Founder’s Briefing: The Day’s Top Product Hunt Picks Decoded by a Builder

An AI-designed drug just showed it can reverse lung function decline in patients with a fatal disease. In a Phase Two trial for idiopathic pulmonary fibrosis, patients on Insilico Pharma's rentosertib saw their lung capacity improve by ninety-eight-point-four milliliters, while those on placebo got worse. Last time we talked about spotting real innovation versus just noise. Well, today we have the perfect case study, showing what happens when AI is used to solve a foundational problem, not just as a marketing gimmick. So here's what else is moving. First, a new approach to energy storage is getting major recognition. A company called Torus just had its Nova Spin system—it's an advanced flywheel—named one of TIME’s Best Inventions.

Instead of chemical batteries, it stores energy mechanically in a spinning mass. The key change here is speed. It can deliver power ten times faster than traditional batteries, in under two hundred fifty milliseconds. That's fast enough to stabilize a grid when a cloud passes over a solar farm. It's built from ninety-five percent recyclable materials and lasts over twenty-five years, which completely changes the math on long-term energy infrastructure. Second, SAP is finally tackling upstream supply chain risk. For years, you’ve been able to see disruptions in your own warehouses, but what about your supplier’s supplier? SAP just rolled out an intelligent impact analysis tool that uses AI to scan both internal and external signals for early warnings.

It’s designed to stop you from finding out about a critical component shortage only when the truck doesn't show up. It’s a shift from reactive to predictive risk management. And third, for anyone building software, the problem of test debt is getting a new solution. A platform called Functionize is using AI to automate the whole testing process. Now, automated testing isn't new, but here's the delta: it uses self-healing tests that automatically adapt when you make small changes to your app. That's the part that kills most teams—the constant maintenance. This promises to let non-technical users create tests and actually reduce the backlog, instead of just adding to it. Okay, let's go back to that drug trial, because it connects directly to the biggest conversation happening on Product Hunt right now.

The drug is called rentosertib. It's a TNIK inhibitor, which means it targets a mechanism in the body that the AI platform identified as a key driver of fibrosis. And the trial results weren't just a statistical blip—biomarkers confirmed it was having anti-fibrotic and anti-inflammatory effects. This is the absolute opposite of hype. It's an AI platform that went from a novel hypothesis to a clinically validated drug candidate that might actually SAVE lives. Now, contrast that with what product leader Mona Truong just posted in a discussion on Product Hunt. She said, "The ones that succeed make AI invisible. The user just notices the product works better… Let users pull, don’t push." This is the core tension. Insilico’s AI is invisible to the patient.

They don't care about the algorithm; they care that they can BREATHE. The AI was a tool to solve the problem, not the product itself. So many of the AI features we see fail because they are "pushed" on you. It's a solution looking for a problem. A button that says "rewrite with AI" that you never click. But the products that win are the ones where you "pull" the capability without thinking. Think of Granola's meeting notes—people just stop noticing the AI is there, they just know their notes are always perfect. That’s the goal. Functionize, the testing platform, is another example. The value isn't "AI-powered tests." The value is you go home an hour earlier because you're not fixing broken test scripts all day. The AI is just the mechanism.

The biggest mistake isn't choosing the wrong AI tool. As one expert put it, it's solving the wrong problem. So when you're looking at the next big thing, the question isn't "Does it use AI?" The question is "Does it make a painful, expensive, or impossible problem suddenly trivial?" Insilico's AI didn't just write a better description for a mattress; it found a new way to stop scar tissue from forming in human lungs. That's the difference between a capability and a solution. And right now, that's the only difference that matters.